Kim T Arndt, PhD

Vice President, Oncology Scientific Strategy
Media Name: kim_arndt_050418_300x170.jpg

After my postdoctoral fellowship at the Whitehead Institute/MIT, I went to Cold Spring Harbor Laboratory as a Senior Staff Investigate where we used yeast as a model organism to study novel mechanisms for regulation of cell cycle and cell growth. After 9 years, I moved to Wyeth Research in 1996 with a desire to translate science into treatment of human cancer. During this time, I led a group that developed Bosulif: an Abl/Src kinase inhibitor that is approved for relapsed and first line chronic myelogenous leukemia. Pfizer acquired Wyeth in 2009 and after serving as Vice President of Oncology Target Discovery within the Pfizer Oncology Research organization, I am currently Vice President of Oncology Scientific Strategy.


I manage coordination of Oncology Scientific Strategy and the project portfolio through collaboration with our three Chief Scientific Officers in the Oncology Research Division. We review external scientific innovation and business development partnering opportunities.


  1. Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth.
    Oncotarget. 2015 6:2928-2938.
    Barsotti AM, Ryskin M, Zhong W, Zhang WG, Giannakou A, Loreth C, Diesl V, Follettie M, Golas J, Lee M, Nichols T, Fan C, Li G, Dann S, Fantin VR, Arndt K, Verhelle D, Rollins RA
  2. Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment.
    Clinical Cancer Research. 2015 21(13): 1-6.
    VanArsdale T, Boshoff C, Arndt KT, Abraham RT
  3. Efficacy of SERD/SERM Hybrid-CDK4/6 inhibitor combinations in models of endocrine therapy resistant breast cancer.
    Clinical Cancer Research. 2015 21:5121-5130.
    Wardell SE, Ellis MJ, Alley HM, Eisele K, VanArsdale T, Dann SG, Arndt KT, Primeau T, Griffin E, Shao J, Crowder RJ, Lai JP, Norris JD, McDonnell DP, Li S.


Albright College, B.S. in Biochemistry, 1975
University of Pennsylvania, Ph.D. in Biochemistry, 1981
University of Pennsylvania, Postdoctoral Fellow, 1984
Whitehead Institute/MIT, Postdoctoral Fellow, 1988


Sigma Xi Outstanding Ph.D. Dissertation Award, 1981
Wyeth Eagles Program (development program of top performers in R&D), 2002 – 2004
Winner: Pfizer Oncology B> "Colleague of the Year"; For discovery of BOSULIF for the treatment of CML, 2016

It is a joy to work at Pfizer where every day you wake up and face the incredible challenges of learning many new things, the excitement of discovering new science, and the satisfaction of translating your efforts into therapies that extend the lives of cancer patients. There is no better job in the world.